Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SUHENDAN EKMEKCIOGLU and ELIZABETH A GRIMM.
SUHENDAN EKMEKCIOGLU
Connection Strength
6.167
ELIZABETH A GRIMM
  1. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res. 2013 Oct 15; 19(20):5557-63.
    View in: PubMed
    Score: 0.458
  2. Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutr Cancer. 2011; 63(6):940-9.
    View in: PubMed
    Score: 0.398
  3. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine. 2008 Jul; 43(1):34-44.
    View in: PubMed
    Score: 0.321
  4. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide. 2008 Sep; 19(2):133-7.
    View in: PubMed
    Score: 0.319
  5. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006 Aug 15; 119(4):861-6.
    View in: PubMed
    Score: 0.283
  6. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets. 2005 Mar; 5(2):103-15.
    View in: PubMed
    Score: 0.256
  7. Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Res Commun. 2023 07; 3(7):1397-1408.
    View in: PubMed
    Score: 0.230
  8. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther. 2003 Jan; 2(1):9-17.
    View in: PubMed
    Score: 0.221
  9. Correction: Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis. 2022 May 02; 13(5):422.
    View in: PubMed
    Score: 0.211
  10. Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis. 2022 02 04; 13(2):117.
    View in: PubMed
    Score: 0.207
  11. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer. 2001 Oct 01; 94(1):54-9.
    View in: PubMed
    Score: 0.202
  12. iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Front Oncol. 2021; 11:631766.
    View in: PubMed
    Score: 0.194
  13. The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival. Cancers (Basel). 2020 Dec 14; 12(12).
    View in: PubMed
    Score: 0.191
  14. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2000 Dec; 6(12):4768-75.
    View in: PubMed
    Score: 0.191
  15. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res. 1999 Jun; 9(3):261-72.
    View in: PubMed
    Score: 0.172
  16. Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy. Front Oncol. 2018; 8:67.
    View in: PubMed
    Score: 0.158
  17. Targeting iNOS to increase efficacy of immunotherapies. Hum Vaccin Immunother. 2017 05 04; 13(5):1105-1108.
    View in: PubMed
    Score: 0.146
  18. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther. 2016 10; 15(10):2442-2454.
    View in: PubMed
    Score: 0.141
  19. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.
    View in: PubMed
    Score: 0.136
  20. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?. J Invest Dermatol. 2015 Nov; 135(11):2901.
    View in: PubMed
    Score: 0.131
  21. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?. J Invest Dermatol. 2015 Nov; 135(11):2775-2784.
    View in: PubMed
    Score: 0.130
  22. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell Melanoma Res. 2013 Jan; 26(1):97-112.
    View in: PubMed
    Score: 0.109
  23. Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer. 2012 Jul 15; 131(2):E56-65.
    View in: PubMed
    Score: 0.103
  24. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer. 2012 Aug 15; 131(4):891-901.
    View in: PubMed
    Score: 0.102
  25. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res. 2011 Feb; 21(1):44-56.
    View in: PubMed
    Score: 0.097
  26. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011 Jan 15; 17(2):229-35.
    View in: PubMed
    Score: 0.095
  27. Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res. 2006 Dec; 26(12):877-86.
    View in: PubMed
    Score: 0.072
  28. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene. 2006 Jun 29; 25(28):3956-62.
    View in: PubMed
    Score: 0.068
  29. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 2004 Dec; 10(6):1085-95.
    View in: PubMed
    Score: 0.063
  30. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res. 2004 Jun; 14(3):165-71.
    View in: PubMed
    Score: 0.061
  31. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002 Jun 15; 168(12):6041-6.
    View in: PubMed
    Score: 0.053
  32. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 2002 Feb 15; 20(4):1069-74.
    View in: PubMed
    Score: 0.052
  33. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res. 2019 03 01; 25(5):1650-1663.
    View in: PubMed
    Score: 0.042
  34. High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 12; 2:1-12.
    View in: PubMed
    Score: 0.042
  35. Mitochondrial dynamic alterations regulate melanoma cell progression. J Cell Biochem. 2019 Feb; 120(2):2098-2108.
    View in: PubMed
    Score: 0.041
  36. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol. 2017; 8:689.
    View in: PubMed
    Score: 0.038
  37. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia. 2017 03; 19(3):237-249.
    View in: PubMed
    Score: 0.037
  38. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep. 2016 10 20; 6:35848.
    View in: PubMed
    Score: 0.036
  39. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res. 2016 May; 29(3):297-308.
    View in: PubMed
    Score: 0.034
  40. Dual Roles of RNF2 in Melanoma Progression. Cancer Discov. 2015 Dec; 5(12):1314-27.
    View in: PubMed
    Score: 0.033
  41. Inflammatory IL-1?-driven JNK activation in stage III melanoma. Pigment Cell Melanoma Res. 2015 Mar; 28(2):236-9.
    View in: PubMed
    Score: 0.032
  42. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol. 2014 Aug; 7(4):484-92.
    View in: PubMed
    Score: 0.031
  43. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res. 2014 Feb 15; 74(4):1067-78.
    View in: PubMed
    Score: 0.030
  44. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40.
    View in: PubMed
    Score: 0.027
  45. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res. 2011 Nov; 9(11):1537-50.
    View in: PubMed
    Score: 0.025
  46. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44.
    View in: PubMed
    Score: 0.023
  47. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008 Dec; 7(12):3842-51.
    View in: PubMed
    Score: 0.021
  48. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5.
    View in: PubMed
    Score: 0.020
  49. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother. 2007 Feb; 56(2):205-15.
    View in: PubMed
    Score: 0.017
  50. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan; 11(1):160-72.
    View in: PubMed
    Score: 0.016
  51. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol. 2004 May; 4(5):649-67.
    View in: PubMed
    Score: 0.015
  52. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther. 2002 Oct; 1(12):1009-17.
    View in: PubMed
    Score: 0.014
  53. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med. 2002 Aug; 8(8):451-61.
    View in: PubMed
    Score: 0.013
  54. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther. 1998 Feb; 5(2):189-95.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.